OCREVUS J Code: J2350

Drug & Product Overview

HCPCS Descriptor Injection, ocrelizumab, 1 mg

HCPCS Added Date January 1, 2018

Manufacturer Genentech

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About OCREVUS

Ocrevus is a medication aligned to the HCPCS J Code: J2350 for billing, pricing, and reimbursement purposes in the United States. It is a Neurology drug administered via the intravenous route and manufactured by Genentech.

According to CMS Drug Use Information: Ocrelizumab is used to treat certain forms of multiple sclerosis-MS (relapsing or primary progressive forms). It is not a cure for MS, but it is thought to help slow down nerve damage, reduce the number of relapses, and delay disability. Ocrelizumab belongs to a class of drugs known as monoclonal antibodies.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
50242-0150-01	Ocrevus	Genentech, Inc.	300	300 MG / 10 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

OCREVUS Pricing & Reimbursement

J2350 Private Payer Reimbursement

$59.56 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

OCREVUS Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 16.32%

Avg. Days to File 11.1days

Avg. Days to Pay 27.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J2350 claims analytics on FocalPoint →

OCREVUS CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

CMS does not include Ocrevus (J2350) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J2350. Wastage billing guide →

OCREVUS Medically Unlikely Edits (MUE)

The most billing units of J2350 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

600 units / day

= 600 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

OCREVUS Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Primary progressive multiple sclerosis Relapsing forms of multiple sclerosis Relapsing-remitting multiple sclerosis

Drug Class

AntibodiesMonoclonal [CS]MonoclonalHumanized [CS]CD20-directed Antibody Interactions [MoA]CD20-directed Cytolytic Antibody [EPC]

Frequently Asked Questions

Is there an available Ocrevus billing and coding guide?

Billing and coding information for OCREVUS can be found through Genentech. Visit Here →

Are there any available Ocrevus patient assistance programs?

OCREVUS patient assistance information can be found through Genentech. Visit Here →

Where can I find Ocrevus prescribing information?

OCREVUS prescribing information can be found at the link below: Visit Here →

Where can I find Ocrevus side effect information?

Information regarding OCREVUS's side effects can be found at MedlinePlus Visit Here →

Does billing OCREVUS require JZ/JW wastage modifiers?

CMS does not include OCREVUS (J2350) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J2350. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.